Sol-Gel sets Nov. 17 annual meeting, proposes renaming to Sol-Gel Therapeutics or Dermatology

Sol-Gel Technologies Ltd. filed a notice and proxy statement for its Annual Meeting of Shareholders, to be held November 17, 2026 at 9:00 a.m. Eastern Standard Time at Greenberg Traurig's offices in New York. Shareholders who hold ordinary shares as of the close of business on October 7, 2026 are entitled to vote at the meeting.¹

The agenda includes six proposals. Shareholders will vote on appointing Kesselman & Kesselman as independent auditors for 2026, and on re-electing Moshe Arkin, Itai Arkin, Hanna Lerman, and Sharon Kochan to the board for an additional term until 2027.¹ A separate proposal covers the re-election of Ran Gottfried and Yuval Yanai as external directors for new three-year terms.¹

A key item asks investors to approve appointing Moshe Arkin, the current interim CEO, Executive Chairman and the company's controlling shareholder, to serve as CEO for an additional three-year term, effective January 1, 2027¹. The filing notes Arkin beneficially holds, directly and through his wholly owned subsidiary M. Arkin Dermatology Ltd., approximately 56% of the company's outstanding shares¹. Arkin will not receive compensation for his roles as Executive Chairman and CEO, aside from reimbursement of reasonable out-of-pocket expenses.¹

Shareholders will also vote on changing the company's name to "Sol-Gel Therapeutics Ltd." or "Sol-Gel Dermatology Ltd." or a similar name containing "Sol-Gel," subject to Israel Registrar of Companies approval, within 12 months of the meeting¹, and on increasing the company's registered share capital¹. Under the proposal, the registered share capital would rise from 5,000,000 to 8,000,000 ordinary shares, par value NIS 1.00 each.¹

As of October 6, 2026, the company had 3,273,999 ordinary shares issued and outstanding.¹ Final voting results will be published after the meeting in a Form 6-K filed with the SEC.¹